Latest news

• Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

  ALK inhibitor improved progression-free survival in first-line setting. Results from a phase 3 study of Pfizer’s third-generation ALK inhibitor Lorbrena have come back positive as the pharma ... other healthcare providers, as well as engage with global

• Pfizer’s Talzenna cleared for breast cancer in Europe

  Fourth to market aims to carve out niche. EU regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with BRCA-mutated breast cancer, opening up another front in a ... Talzenna is one of four new targeted therapies it is hoping will

• Pfizer gets EU nod for Tagrisso rival Vizimpro

  Last November, the drugmaker claimed FDA approval for Xalkori follow-up Lorbrena (lorlatinib) in second-line ALK-positive NSCLC and SMO inhibitor Daurismo (glasdegib) for acute myeloid leukaemia, while in October ... it got a green light for PARP

• Pfizer claims rapid FDA nod for Lorbrena

  The FDA has granted approval to Pfizer's next generation ALK inhibitor lung cancer treatment Lorbrena, which will help it defend its presence in the market. ... Follow-up ALK inhibitors are important in this treatment pathway, as many experience tumour

• Pfizer’s flat sales focus investor attention on M&A

  Among the highlights cited by Read on the call were oncology drugs talazoparib - a PARP inhibitor due for filing shortly for breast cancer - along with ALK/ROS1 inhibitor lorlatinib and EGFR ... inhibitor dacomitinib for lung cancer, which are due for